Two Washington Post articles sparked an online debate about the potential mental health effects of GLP-1 weight loss medications. A May 23 article discussed reports from some people taking the medications who said they developed new eating disorders or experienced a relapse of an existing disorder. In response, some online users shared their own experiences with eating disorders while taking the medications, with some suggesting the drugs improved their symptoms. Others claimed it was “obvious” that the medications would cause or worsen eating disorders. A May 28 article described recent research suggesting that GLP-1s may be “reshaping” the brains of people taking them. Some dismissed the article as “fear-mongering,” while others noted that the finding could help inform future research on addiction, cognition, and neurodegenerative diseases like Alzheimer’s.
Social media and Reddit posts also claimed that GLP-1s caused suicidal thoughts, mood swings, and emotional “flatness.” Some users said that the medications helped reduce intense cravings and binge eating, while others reported that they worsened depression and interfered with ADHD medications.
Recommendation
Online conversations about GLP-1s may resurface misconceptions about the medications and raise questions about their risks and benefits. Health communicators may emphasize that only a health care provider can help individuals determine whether GLP-1s are appropriate for them based on their specific health needs. Messaging may explain that GLP-1s mimic natural hormones involved in regulating hunger and digestion and that research suggests they may provide additional health benefits. Explaining that GLP-1s are generally considered safe when prescribed and taken under the supervision of a health care provider is recommended, as is noting that some people may experience mild to moderate side effects that often improve over time. Communicators may also encourage people to speak to their health care provider about any mental health concerns they may have before, during, or after taking GLP-1 medications.
Fact-checking sources: University of Utah Health, Tufts Medicine
Communication resources: Find more resources to communicate about mental health
